These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10262075)

  • 1. New drug and antibiotic regulations--FDA. Proposed rule.
    Fed Regist; 1982 Oct; 47(202):46622-66. PubMed ID: 10262075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
    Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of regulations regarding certification of drugs composed wholly or partly of insulin; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(92):26690-3. PubMed ID: 10179340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administrative practices and procedures; internal agency review of decisions; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(115):32772-4. PubMed ID: 10180279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
    Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); companion document to direct final rule. Food and Drug Administration, HHS. Proposed rule.
    Fed Regist; 1999 May; 64(93):26344-8. PubMed ID: 10558531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(223):64222-8. PubMed ID: 10339051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administrative practices and procedures; internal review of agency decisions---FDA. Direct final rule.
    Fed Regist; 1998 Jun; 63(115):32733-5. PubMed ID: 10180278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General administrative rulings and decisions; amendment to the examination and investigation sample requirements; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Sep; 63(186):51322-4. PubMed ID: 10185811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Removal of regulations regarding certification of antibiotic drugs--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(91):26066-9. PubMed ID: 10179333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.